From Control to Innovation: Kanghua Bio's Strategic Acquisition of Narnexis Strengthens Its mRNA Platform

On January 28, 2026, Chengdu Kanghua Biological Products Co., Ltd. (Stock Code: 300841.SZ, hereinafter referred to as “Kanghua Biological”) announced a phased acquisition of NanoRibo (Shanghai) Biotechnology Co., Ltd. (hereinafter referred to as “NanoRibo”). This marks the first public revelation of a strategic merger and acquisition completed by Kanghua Biological under the leadership of the Shanghai Biomedical M&A Fund (hereinafter referred to as the “M&A Fund”), following its acquisition of a controlling stake in Kanghua Biological for RMB 1.851 billion in November 2025. These are not two simple, independent capital operations, but rather a concrete implementation of a new investment paradigm: “Fund Control – Platform Integration – R&D.” Through this acquisition, the M&A Fund has assisted Kanghua Biological in systematically establishing a synergistic development model featuring “Shanghai R&D (NanoRibo Technology Center) + Chengdu Industrialization (Kanghua Biological Production Base) + Nationwide Commercialization (Shanghai Pharmaceutical Distribution System).”

In this transaction, Kanghua Biologics has placed particular emphasis on NanoRibo’s next-generation mRNA vaccine technology platform, which boasts significant differentiated advantages, as well as its “hardcore” team that combines profound scientific expertise with extensive industrialization experience. Empowered by the merger and acquisition fund, Kanghua Biologics has strategically invested in NanoRibo, a Shanghai-based innovative technology enterprise, to strengthen the capabilities and elevate the operational level of its Shanghai R&D center’s new technology platform. Upon completion of the transaction, Kanghua Biologics will accelerate its transformation from a steadily operating vaccine product company into a biomedical innovation platform equipped with cutting-edge technological engines and platform integration capabilities. This transaction will further contribute to Shanghai’s development as a global hub for biomedical R&D and industrialization.

Amidst the industry’s cyclical adjustment, a buyout fund is leading this integration with the aim of helping Kangh establish robust technical barriers and cultivate long-term clinical value. NanoRibo is precisely the “hard-core technology” enterprise that meets these criteria. Founded in May 2021, NanoRibo’s founding team boasts over 20 years of accumulated expertise in virology, immunology, and vaccines, with core members possessing experience in mRNA research, development, and industrialization at large multinational corporations (MNCs). More critically, guided by a differentiated “long-termism” R&D philosophy, NanoRibo has established three major technology platforms as its foundation for growth: AI-based antigen and codon optimization tools (including its proprietary CodonBox and AntigenBoost), which enhance mRNA translation efficiency and protein expression stability; a breakthrough mRNA-LNP lyophilization process that enables long-term stable storage of products at 2–8°C; and an LNP delivery system incorporating novel ionizable lipids, which is better adapted to NanoRibo’s proprietary lyophilization process, thereby comprehensively improving product safety and immunogenicity.

NanoRibo’s core product, the mRNA RSV vaccine (NR222), is the first freeze-dried mRNA vaccine candidate to file for clinical trials in China [it received implicit approval for clinical trials from the Center for Drug Evaluation (CDE) of the National Medical Products Administration in December 2024 (Acceptance Number: CXSL2400681)]. Its ability to remain stable during long-term storage at 2–8°C directly addresses a critical industry pain point, resolving the long-standing challenge of cold-chain transportation. Furthermore, preclinical data demonstrate that NanoRibo’s NR222 elicits higher neutralizing antibody titers and superior protective efficacy compared to currently marketed recombinant protein vaccines in cotton rat challenge models, with a favorable safety profile. Meanwhile, the company has strategically positioned its forward-looking pipeline in areas such as HSV, autoimmune diseases, and oncology, building a sustainable tier of innovative products. This transaction not only adds a clinical-stage RSV vaccine pipeline to Kanghua Biologicals but also systematically strengthens Kanghua Biologicals’ next-generation mRNA vaccine technology platform, creating an “innovation engine” with significant differentiated advantages for Kanghua Biologicals.

“What we aim to do is to develop products with genuine clinical value.” This statement by Deng Ming, Co-founder and CEO of NanoRibo, encapsulates the company’s core values. Its solid scientific foundation, systematic platform capabilities, and pragmatic product orientation make it a worthwhile target for investment and integration at this stage.

For Kanghua Biological, this transaction represents a strategic “leap” in its development journey. With its freeze-dried human rabies vaccine (human diploid cell) as the core product, Kanghua Biological has established stable cash flow and market reputation; its recombinant hexavalent norovirus vaccine has obtained clinical trial approvals in China, the United States, and Australia, demonstrating certain R&D capabilities. However, to build a future-oriented and internationally competitive vaccine platform, Kanghua Biological must proactively layout next-generation frontier technologies.

mRNA technology integrates cutting-edge, multidisciplinary advances in molecular biology, computational science, synthetic chemistry, and formulation engineering. Characterized by rapid technological iteration and high platform barriers, relying solely on internal R&D to quickly build comprehensive, independent, and differentiated core technical capabilities presents multiple practical challenges. Therefore, the strategic acquisition and integration of NanoRibo, an innovative company possessing proprietary technologies and a top-tier team, represents an effective pathway for Kangh to rapidly acquire key core technologies and complete its capability portfolio. This transaction is not merely a simple aggregation of resources, but rather a proactive positioning within the innovation ecosystem and a strategic restructuring of the technological paradigm. Post-transaction, NanoRibo will serve as Kangh’s mRNA R&D platform in Shanghai, focusing on underlying technology development and early-stage pipeline innovation, thereby enabling leapfrog development of Kangh’s existing mRNA platform capabilities. This deal achieves a win-win outcome: Kangh’s mature industrialization capabilities, quality management systems, and commercialization channels will accelerate NanoRibo’s process scale-up, clinical advancement, and future commercialization; meanwhile, NanoRibo’s frontier platform technologies and innovative pipeline will provide Kangh with a predictable “second growth curve” and a technological “moat” to address future competition.

M&A funds serve as “anchors for strategic direction” and “bridges for innovative resources.” After taking control of Kanghua Biological, the M&A fund participated deeply in its strategic planning, clearly establishing the construction of a next-generation mRNA technology platform as the anchor direction for Kanghua Biological’s leapfrog development. The M&A fund’s selection of NanoRibo, a Shanghai-based innovative enterprise, as the target of this transaction demonstrates the fund’s professional insight and extensive network, proving that resource integration between industrial companies and frontier innovations can be achieved under capital leadership.

This transaction establishes a synergistic model of “Shanghai R&D – Chengdu Industrialization – China-wide Commercialization,” accelerating the industrial translation of biopharmaceutical technological innovations from Shanghai. The M&A fund not only supports Kanghua Biological’s acquisition of in-development product pipelines but also aims to position NanoRibo as an indispensable “innovation engine” for Kanghua Biological. In the future, Kanghua Biological and NanoRibo can achieve complementary advantages and mutual empowerment. This partnership will fully activate and enhance the R&D innovation efficiency of Shanghai’s biopharmaceutical industry, while fostering deep synergy between Chengdu’s efficient industrial base and Shanghai’s R&D capabilities, jointly building a competitive technology and translation platform for Kanghua Biological’s future growth.

Completing the M&A transaction is merely the starting point; technological integration, team assimilation, and management empowerment are the keys to value realization. Following the closure of this transaction, the M&A fund will continue to “escort” Kangh and NanoRibo in achieving deep integration, ensuring long-term synergistic value for both parties and propelling Kangh’s transformation into a globally competitive, technology-platform-driven vaccine enterprise.

M&A funds are forging a new development path of “capital empowering industry” through a full-chain operational model of “controlling stake–strategic decision-making–enablement–integration.” By leveraging capital as the link and listed companies as platforms, these funds guide financial resources toward innovative enterprises with core hard-tech capabilities, promoting the transformation of cutting-edge technologies into industrial competitiveness and long-term value through systematic strategic integration. In the future, NanoRibo will serve as Kangh’s innovation and R&D platform in Shanghai, continuing to root itself in the city, attract high-end talent, and pursue source innovation. Through the listed company Kangh, it will radiate its innovative achievements across China and globally, thereby strengthening and upgrading Shanghai’s local innovation capacity and fostering the prosperity and refinement of Shanghai’s biomedical innovation industry chain.